We have previously described a 40 kDa colonic protein(s) which is specifically recognised by tissue-bound immunoglobulin G obtained from the colon of patients with ulcerative colitis. We now report the presence of circulating antibodies against this antigen using an enzyme-linked immunosorbent assay with a highly enriched preparation of the 40 
Idiopathic ulcerative colitis is a chronic inflammatory disease of the large intestine, the aetiology and pathogenesis of which are unclear. Autoimmunity has been suggested in the pathogenesis of ulcerative colitis because of the presence of circulating and local antibodies that react with unknown alimentary tract antigens and because of the striking increase in immunoglobulin G (IgG) secreting plasma cells observed in the mucosa of patients with this disorder. ' 40 kDa protein has been localised to the colonic epithelial cell membrane and its organ specificity is further shown. 8 These findings suggest that the 40 kDa protein may represent an autoantigen in ulcerative colitis.
In this study, we assessed in patients with ulcerative colitis the presence and specificity of circulating antibodies against the 40 kDa colonic protein by an enzyme-linked immunosorbent assay (ELISA).
Methods

SERA
Sera were collected (mostly at outpatient clinics) from 79 patients with ulcerative colitis, 36 with Crohn's disease, 16 with diarrhoeal syndromes caused by specific pathogen(s) and other causes (Table) , and from 19 normal subjects. During collection of sera, the physician recorded the patients' symptoms according to a specific protocol modified from Harvey and Bradshaw.9 The physicians also recorded whether the patients were symptomatic or in remission.
Patients with diarrhoea (three or more loose bowel movements per day) and with mucus or blood, or both, in the stool were considered symptomatic. Twenty nine of 79 ulcerative colitis and 21 of 36 Crohn's disease patients and all 16 patients with specific diarrhoeal syndromes were symptomatic during collection of sera. Since most of the patients were attending the outpatient clinic, no further classification of severity of the disease -for example, mild, moderate, or severe -was made. Most of the patients with ulcerative colitis were taking sulphasalazine. Twenty patients with ulcerative colitis were taking systemic steroids and five were treated with steroid enema. None of the patients were treated with azathioprine or 6-mercaptopurine. All sera were stored frozen at -80°C until use, and were clarified by centrifugation before dilution and use for the ELISA. horse serum for one hour at 37°C. Clarified sera were diluted in 5% bovine serum albumin in PBS and applied to wells in triplicate. All sera were diluted 1:5 and 1:10 before their use in ELISA.
Blanks consisted of antigen coated wells that were incubated with no human sera and BSA coated wells incubated with human sera. After an incubation of one hour with sera at 37°C, plates were washed, incubated with alkaline phosphatase conjugated anti-human IgG (Cappel, CA) applied in 100 p1 per well at a dilution of 1/500 for one hour at 37°C. Unbound second antibody-enzyme conjugate was removed by washing. Bound alkaline phosphatase was assayed at 37°C with the Sigma substrate with 100 p1 per well in 1 mM magnesium chloride, 50 mM sodium carbonate pH 9 8 distribution. This implies that with a confidence of >95%, one can identify about 55% ofall active ulcerative colitis patients using this ELISA. Only two sera of patients who did not have ulcerative colitis (one with Crohn's disease and one normal subject) had an optical density greater than 0-291, the highest mean optical density plus 2 SD for a non-ulcerative colitis group. This implies the specificity of this assay is 98% when the optical density is at or above 0-291.
The distribution of the symptomatic ulcerative colitis group is very broad -about two thirds of the individual values within this group are below the group mean and the remaining third are above. The means for all other groups were essentially identical to their medians. The median values are: symptomatic ulcerative colitis, 0 3 10; ulcerative colitis in remission 0 113; all Crohn's disease, 0-110; patients with diarrhoeas, 0d119; normal control subjects, 0 120. Thus the symptomatic ulcerative colitis group does not seem as normally distributed as the other groups. Because of this the data were subjected to non-parametric comparison tests, rank sum and Kruskal-Wallis analysis of variance. These tests gave p values even more significant, at p<0-0001 in all comparisons, indicating that the symptomatic ulcerative colitis group was different from all the other groups. Furthermore, when medians rather than means are compared, similar conclusions are reached. The It is possible that in this direct ELISA, ulcerative colitis serum containing immune complexes will not react or react poorly to the 40 kDa protein on the plate because of the bound antibody with the antigen(s) in the complexes. This may account for the finding that some of the ulcerative colitis sera did not show high optical density. Although circulating immune complexes have been described in patients with inflammatory bowel disease," it is not known whether 40 kDa protein constitutes an antigen component(s) in these complexes. Further studies are needed to examine for specific antigen(s) in the immune complexes isolated from patients with ulcerative colitis and appropriate controls.
Specific autoantibodies against various target cell components have contributed to our understanding of the pathogenesis of various autoimmune diseases. Double stranded DNA in systemic lupus erythematosus, insulin receptor in juvenile diabetes mellitus, thyroglobulin in autoimmune thyroiditis, and acetylcholine receptor in myasthenia gravis act as organ specific autoantigens in these diseases. [12] [13] [14] [15] [16] Many patients who are acutely ill have high titres of these specific autoantibodies, and monitoring these circulating autoantibodies was very helpful in the diagnosis and in assessing the clinical course. [13] [14] [15] [16] In the current study, a positive correlation of the optical density values with activity of the disease state was evident. While ulcerative colitis patients with active disease had significantly higher optical densities, patients in remission did not. Future studies are needed to evaluate critically the relation between clinical severity and the titre of the anti-40 kDa antibodies in the same group of patients when they undergo remission after treatment. It is interesting that two patients with ulcerative colitis had a higher preoperative optical density value which dropped during the postoperative period. Three patients who had sera collected at symptomatic and remission stages also showed a decline in optical density values after remission. Since the patients in this series were followed as outpatients and most of them did not have barium enema or colonoscopy during the time of collection of serum, the precise extent of the disease and its relation with the antibody titre could not be evaluated.
This study supports the notion that the 40 kDa protein acts as at least one autoantigen in patients with ulcerative colitis. 
